Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm TrialAndrew R. Branagan, Madhav V. Dhodapkar, Lin Zhang et al.|Clinical Lymphoma Myeloma & Leukemia|2017Cited by 48
Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell DisordersAndrew R. Branagan, Madhav V. Dhodapkar, Eamon Duffy et al.|Blood|2017Cited by 6
Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical TrialAndrew R. Branagan, Madhav V. Dhodapkar, Eamon Duffy et al.|Blood|2016Cited by 2
Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell DisordersAndrew R. Branagan, Madhav V. Dhodapkar, Eamon Duffy et al.|Blood|2015Cited by 1
2168Andrew R. Branagan, Madhav V. Dhodapkar, Eamon Duffy et al.|Journal of Clinical and Translational Science|2017Cited by 0